EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis

Cheng Chen iD, Michael P Douglas, Meera V Ragavan, Kathryn A Phillips, Jeroen P Jansen

Molecular Diagnosis & Therapy · 2024-09 · 28 (5) · 525-536

DOI: 10.1007/s40291-024-00725-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 02.08.2024. Verfasst von Cheng Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Circulating tumor DNA (ctDNA) testing has become a promising tool to guide first-line (1L) targeted treatment for advanced non-small cell lung cancer (aNSCLC). This study aims to estimate the clinical validity (CV) and clinical utility (CU) of ctDNA-based next-generation sequencing (NGS) for oncogenic driver mutations to inform 1L treatment decisions in aNSCLC through a systematic literature review and meta-analysis. METHODS: A systematic literature search was conducted in PubMed/MEDLINE and Embase to identify randomized control trials or observational studies reporting CV/CU on ctDNA testing in patients with aNSCLC. Meta-analyses were performed using bivariate random-effects models to estimate pooled sensitivity and specificity. Progression-free/overall survival (PFS/OS) was summarized for CU studies. RESULTS: A total of 20 studies were identified: 17 CV only, 2 CU only, and 1 both, and 13 studies were included for the meta-analysis on multi-gene detection. The overall sensitivity and specificity for ctDNA detection of any mutation were 0.69 (95% CI 0.63-0.74) and 0.99 (95% CI 0.97-1.00), respectively. However, sensitivity varied greatly by driver gene, ranging from 0.29 (95% CI 0.13-0.53) for ROS1 to 0.77 (95% CI 0.63-0.86) for KRAS. Two studies that compared PFS with ctDNA versus tissue-based testing followed by 1L targeted therapy found no significant differences. One study reported OS curves on ctDNA-matched and tissue-matched therapies but no hazard ratios were provided. CONCLUSIONS: ctDNA testing demonstrated an overall acceptable diagnostic accuracy in patients with aNSCLC, however, sensitivity varied greatly by driver mutation. Further research is needed, especially for uncommon driver mutations, to better understand the CU of ctDNA testing in guiding targeted treatments for aNSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsHumansHigh-Throughput Nucleotide SequencingMutationSensitivity and Specificity

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA, USA.
  • Division of Hematology and Oncology, UCSF Department of Medicine, San Francisco, CA, USA.
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • UCSF Philip R. Lee Institute for Health Policy, San Francisco, CA, USA.
  • Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA, USA. jeroen.jansen@ucsf.edu.
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. jeroen.jansen@ucsf.edu.

ORCID-Profile: Cheng Chen

Förderung

  • NHGRI NIH HHS
  • National Human Genome Research Institute
  • National Cancer Institute

Zitieren

APA

Chen, C., Douglas, M. P., Ragavan, M. V., Phillips, K. A., & Jansen, J. P. (2024). Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Molecular Diagnosis & Therapy, 28(5), 525-536. https://doi.org/10.1007/s40291-024-00725-x

Vancouver

Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Molecular Diagnosis & Therapy. 2024;28(5):525-536. doi:10.1007/s40291-024-00725-x

BibTeX
@article{Chen2024,
  author = {Chen, Cheng and Douglas, Michael P and Ragavan, Meera V and Phillips, Kathryn A and Jansen, Jeroen P},
  title = {Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis},
  journal = {Molecular Diagnosis & Therapy},
  year = {2024},
  volume = {28},
  number = {5},
  pages = {525--536},
  doi = {10.1007/s40291-024-00725-x}
}
Kostenlos starten →